This clinical trial, sponsored by Western University of Health Sciences, investigates the potential of OMT to augment the immune response to mRNA COVID-19 vaccines. Given the ongoing concerns regarding vaccine efficacy against emerging variants, successful outcomes could position OMT as a complementary therapy in vaccination protocols, potentially expanding market opportunities within the immunotherapy and vaccine enhancement sectors. The trial's completion suggests readiness for further exploration of OMT in broader vaccine contexts, which may attract interest from pharmaceutical companies and healthcare providers looking to enhance vaccine efficacy. Competitive implications include the potential for OMT to differentiate vaccine offerings in a crowded market, particularly as public health strategies evolve.